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Abstract: The development of selective tumor targeting agents to deliver multiple units of 
chemotherapy drugs to cancer tissue would improve treatment efficacy and greatly advance 
progress in cancer therapy. Here we report a new drug delivery system based on a tetrabranched 
peptide known as NT4, which is a promising cancer theranostic by virtue of its high cancer 
selectivity. We developed NT4 directly conjugated with one, two, or three units of paclitaxel and an 
NT4-based nanosystem, using NIR-emitting quantum dots, loaded with the NT4 tumor-targeting 
agent and conjugated with paclitaxel, to obtain a NT4-QD-PTX nanodevice designed to 
simultaneously detect and kill tumor cells. The selective binding and in vitro cytotoxicity of NT4-
QD-PTX were higher than for unlabeled QD-PTX when tested on the human colon adenocarcinoma 
cell line HT-29. NT4-QD-PTX tumor-targeted nanoparticles can be considered promising for early 
tumor detection and for the development of effective treatments combining simultaneous therapy 
and diagnosis. 
Keywords: drug delivery; selective tumor-targeting agent; theranostic nanodevices; paclitaxel 
 
1. Introduction 
Drug delivery systems can enhance therapeutic effects and have fewer side- and adverse effects, 
as well as reduced chemotherapic toxicity. A challenge for pharmacology is to find the best 
formulation and the most suitable route of administration to achieve these goals.  
Peptide-based systems may be used in drug delivery, owing to specific chemical properties of 
peptides, which are easy to obtain by chemical synthesis and can be modified to deliver therapeutic 
agents including drugs and diagnostic molecules. These can be coupled to the carrier peptide by 
tailored chemical bonds [1–3]. 
Drawbacks related to peptides as drugs is their short half-life in vivo due to rapid protease 
degradation. In the last few years, several strategies have been considered to improve the metabolic 
stability through chemical approaches aimed to modify the original peptide sequences. A possible 
approach is the introduction of D or other unnatural amino acids, structural constraints, cyclization, 
or transformation of lead peptides into peptidomimetics or small molecules [4]. Peptide proteolytic 
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cleavage can be dramatically reduced by synthetizing peptides in branched form, where multiple 
copies of the same peptide are linked covalently to a branched lysine core [5]. By allowing multimeric 
binding to peptide targets, synthesis in branched form can increase local peptide concentrations and 
biological activity.  
There are currently several peptide-based drug delivery nanosystems in clinical trial phase [6]. 
Nanoparticles, liposomes, and a variety of polymer-based materials are used for carrier construction. 
Nanoparticles are an extremely active field for new drug-delivering carrier development, with 
advantages over other systems. They improve the bioavailability and therapeutic efficiency of 
antitumor drugs, while accumulating preferentially at the tumor site [7–9]. 
Here we report the development of a peptide-based drug delivery system using the tetra-
branched peptide NT4, which is a promising cancer theranostic by virtue of its high cancer selectivity. 
We previously reported a stable tetrabranched peptide, named NT4, which binds with high 
selectivity to human cancer cells and tissues and efficiently and selectively delivers drugs or tracers 
for cancer cell imaging or therapy. We found that the high selectivity of NT4 toward cancer cells and 
tissues resided in its high affinity binding to sulfated glycosaminoglycans [10–14]. 
In a breast cancer orthotopic mouse model, NT4 conjugated with paclitaxel caused tumor 
regression that was not achieved with paclitaxel alone under the same experimental conditions [11]. 
In fact, selective binding of NT4 to cancer cells enabled enhanced local concentrations of the drug in 
cancer tissues and increased tumor cytotoxicity.  
We recently constructed near-infrared quantum dots (QDs) functionalized with NT4 peptide 
(NT4-QDs). We observed specific uptake of NT4-QDs in human cancer cells in vitro, and much higher 
accumulation and retention of targeted QDs at the tumor site, compared to the non-targeted QDs, in 
a mouse colon cancer model [15]. To achieve higher tumor-accumulation of the drug, multiple drug 
moieties can be loaded on a single carrier, reducing the off-target toxicity of the free drug and 
maximizing treatment efficacy [16]. Functionalized nanosystems are precious tools as they can be 
turned into tumor specific probes and can be easily modulated in terms of scale of the carried cargo. 
The possibility of increasing or decreasing the molecular cargo of cytotoxic moieties is necessary to 
fine-tune selectivity and consequently decrease general toxicity. Based on our previous achievements 
[11,15], we tested different technical approaches aimed at developing a peptide-based drug delivery 
system, which could carry multiple cytotoxic units, increasing the efficacy of targeted drug delivery. 
We synthesized different NT4 adducts, where NT4 was covalently coupled to one, two, or three 
molecules of PTX. We also prepared a nanosystem in which a QD nanoparticle was linked to the 
tumor-targeting carrier, i.e., the NT4 peptide, and paclitaxel. The resulting NT4-QD-PTX nanodevice 
was designed to simultaneously detect and kill tumor cells. 
2. Results 
2.1. Paclitaxel for NT4 Multidrug Delivery 
NT4 was solid-phase synthesized and conjugated with a variable number of paclitaxel units. 
Based on previous experience, we selected a Michael reaction between the thiol group of the cysteine 
residue, added to the c-terminal of NT4, and a maleimide group, reversibly linked to the C2-O′ 
oxygen of paclitaxel, to assemble the NT4 multidrug devices. Aiming to minimize any 
pharmacokinetic differences caused by the chemical nature of the linker(s), we designed a common 
spacer bringing a tunable (1–3) number of drug units, namely compounds 3a–c reported in Scheme 
1. Briefly, Paclitaxel (PTX) was regioselectively functionalized at the C-2′ OH by reaction with 6-
azidohexanoic acid to provide derivative PTX-N3 (Scheme 1 step a). Then we prepared O-propargyl 
benzyl succinimides 2a–c from commercially available hydroxy benzoic esters 1a–c. In detail, classic 
propargylation of the phenol groups was followed by reduction of the ester group to the 
corresponding benzyl alcohols that were transformed into derivatives 2a–c under Mitsunobu reaction 
conditions with maleimide, DIAD and Ph3P, and microwave irradiation (Scheme 1, steps b-d). 
Unexpectedly, the yield-limiting step of the procedure was insertion of the maleimide residue in 
benzyl position (i.e., step d). Several strategies were tested, and insertion was eventually achieved 
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under Mitsunobu conditions from the corresponding benzyl alcohols. Working under microwave 
irradiation, we shortened the reaction time and scaled-up the procedure to isolate derivatives 2a–c in 
reasonable amounts. A click copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) was used to 
anchor the drug(s) to PTX-N3. Carried out under classical conditions, CuSO4/sodium ascorbate in 
DMF/H2O, CuAAc led to the isolation of (multi)-functionalized systems, bearing 1 to 3 paclitaxel 
units 3a-c in reasonable yields, as depicted in Scheme 1 step e (supplementary Figures S1, S2, and S3).  
 
Scheme 1. Synthesis of Mono-, Bis- and Tris-PTX conjugates 3a–c. 
2.2. Conjugation of Mono, Bis, and Tris-PTX to NT4  
The NT4 tetrabranched peptide was prepared by automated solid phase synthesis, and after 
isolation was conjugated with a variable number of paclitaxel units (Figure 1). NT4 with a c-terminal 
cysteine moiety was left to react in DMF with paclitaxel carrying maleimide. The addition reaction 
was monitored by HPLC at different times: 1 h, 3 h, 20 h, and 48 h (not shown). When the starting 
materials were consumed, the reaction was stopped by simple removal of solvent under reduced 
pressure, followed by HPLC purification. Identity and purity of the final products 1–3 were 
confirmed by HPLC and mass spectrometry (not shown).  
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Figure 1. Structures of NT4-mono PTX (1), NT4-bis PTX (2), and NT4-tris PTX (3). 
2.3. Cytotoxicity Assay 
Human colon adenocarcinoma HT-29 cells were treated with NT4-mono PTX, NT4-bis PTX, and 
NT4-tris PTX to evaluate the cytotoxicity (Figure 2). In order to minimize the effect of free PTX, 
released from the peptides by hydrolysis of the ester bond after as little as one hour [11], cells were 
incubated for 1 hour and then washed and incubated without the drug for 6 days. 
The conjugation of more than one unit of drug with NT4 proved to have no impact on the overall 
cytotoxic effect, since the three compounds, NT4-mono PTX (1), NT4-bis PTX (2), and NT4-tris PTX 
(3) produced essentially the same effect in this experimental setting. The EC50s of NT4-mono PTX, 
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NT4-bis PTX, and NT4-tris PTX were 1.9 × 10−6 M, 4.6 × 10−6 M, and 2.4 × 10−6 M, respectively. No 
cytotoxic effect was measured using unconjugated NT4 at the same concentrations (not shown). 
 
Figure 2. Cytotoxicity of NT4-mono PTX, NT4-bis PTX, and NT4-tris PTX in HT-29 cell line. 
2.4. Quantum Dot Decoration 
Amine-modified QDs (Qdot 705 ITK amino PEG) were first conjugated with the bifunctional 
cross-linker sulfo-SMCC that provided the maleimide moiety for regiospecific conjugation with the 
Cys-derivative of NT4. PTX was conjugated with the amino residues of the QDs, after transformation 
into PTX-Nsuc (Scheme 2). 
 
Scheme 2. Synthesis of NT4-QD-PTX. 
2.5. Paclitaxel for QDs 
Paclitaxel bearing an activated carboxylic acid was prepared by reaction of PTX with succinic 
anhydride that occurs selectivity at C2′ OH to produce the derivative PTX-COOH (Scheme 3, step a). 
This derivative with its carboxylic acid residue was transformed into the corresponding O-
succinimide derivative PTX-Nsuc with 51% yield (Scheme 3 step b and Supplementary Figure S4). 
PTX-Nsuc carried the activated carboxylic group required for coupling PTX with the NH2 moieties 
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presented on the QDs and a reasonably labile ester group that allowed the release of the cytotoxic 
moiety PTX. 
 
Scheme 3. Synthesis of PTX-Nsuc for QDs coupling. 
QDs were first decorated with sulfo-SMCC that was subsequently used for coupling with NT4 
in the last step of the reaction sequence (Scheme 2). A sub-stoichiometric quantity of sulfo-SMCC was 
used to ensure free amino groups on the nanoparticle for coupling with PTX. Activated PTX, PTX-
Nsuc, was then used in excess to saturate all the amino groups left after the first reaction step. Finally, 
NT4 carrying a cysteine residue at the C-terminus was coupled orthogonally by a Michael reaction 
as already reported in Brunetti J. et al. [11] (Scheme 2). The estimated molar ratio of NT4:PTX, 
calculated on the amino groups of the QD yields a 1:4 ratio. 
2.6. Cell Binding of NT4-QD-PTX 
Binding and internalization experiments of NT4-QD on HT-29 human colon cancer cell line were 
analyzed by immunofluorescence, flow cytometry, and electron microscopy, as described in Brunetti 
J et al. [15]. Previous in vivo imaging experiments in mice bearing HT-29 xenografts showed much 
higher accumulation of NT4-QD than unconjugated QD in tumors [15]. 
Binding of NT4-QD-PTX to human colon adenocarcinoma cell line HT-29 was assessed by 
immunofluorescence and flow cytometry (Figure 3). Cells, incubated with scalar concentrations (20 
µM, 10 µM and 5 µM) of NT4-QD-PTX or with unlabeled QD-PTX, showed a statistically significant 
dose-dependent fluorescent signal (Figure 3B). 
HT-29 cells incubated with 20 nM NT4-QD-PTX showed a fluorescence signal two log higher 
than unlabeled QDs and the difference was statistically significant (Figure 3A). 
Cell binding of NT4-QD-PTX was also analyzed in HT-29 cells by immunofluorescence (Figure 
3C). NT4-QD-PTX bound HT-29 cells (red signal), while no signal was detected with unlabeled QD-
PTX. Nuclei were stained with DAPI (blue signal). 
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Figure 3. Binding of NT4-QD-PTX and unlabeled QD-PTX to HT-29 cell line by flow cytometry and 
immunofluorescence. A) Flow cytometry analysis of 20 nM NT4-QD-PTX (dark grey) and unlabeled 
QD-PTX (light grey) in HT-29 cells. B) Mean fluorescent detected by flow cytometry using scalar 
concentrations of NT4-QD-PTX and unlabeled QD-PTX. *** p < 0.001 calculated using one-tailed 
Student t-test and Graph Pad Prism software. C) Immunofluorescence of NT4-QD-PTX (red signal) 
in HT-29 cell line. Nuclei were stained with DAPI (blue signal). Scale bar 25 µm. 
2.7. Cytotoxicity Assays 
Cytotoxicity of NT4-QD-PTX was tested on HT-29 cells and compared with the cytotoxicity of 
QD-PTX unlabeled with NT4. Different concentrations of QDs were incubated with HT-29 cells for 
one hour and then the cells were washed with medium and allowed to grow for 6 days (Figure 4). 
This procedure was essential to minimize the additive effect of free drug, released from the 
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nanoparticles by hydrolysis of the ester bond. The EC50 of NT4-QD-PTX was 1.3 × 10−8 M and that of 
unlabeled QD-PTX was 4.5 × 10−8 M.  
 
Figure 4. Cytotoxicity of NT4-QD-PTX in HT-29 cell line. Cytotoxicity of NT4-QD-PTX (black line) 
was compared with that of the unlabeled QDs conjugated with paclitaxel (QD-PTX; dotted line). 
3. Discussion 
In the last years, molecularly targeted cancer therapies using antibodies, peptides, scFv, and 
related biomolecules are gaining momentum due to the possibility of improved drug potency and 
efficiency and minimal side effects. Peptides, in particular, can be used for their peculiar cytotoxicity 
or as cytotoxic drug carriers or as tumor specific probes to deliver nanosystems [17–19]. The 
development of selective tumor-targeting agents, whereby a single carrier delivers more than one 
unit of drug to the cancer tissue, would improve treatment efficacy and advance cancer therapy. We 
showed in previous studies that a tetrabranched peptide NT4 has extraordinary selectivity for 
different human cancers (e.g. colon, pancreas and bladder cancer) and can easily be coupled with 
chemical entities or nanoparticles to kill or image cancer cells [13–15,20,21]. Using in vivo 
bioluminescence imaging in an orthotopic mouse model of breast cancer, we previously found that 
conjugation of PTX with NT4 peptide led to increased therapeutic activity of the drug in vivo. NT4-
PTX induced tumor regression, whereas treatment with unconjugated PTX only produced a 
reduction in tumor growth. Moreover, unlike PTX, NT4-PTX is very hydrophilic, which may improve 
its pharmacokinetic profile and allow less toxic dilution buffers to be used, thus decreasing the 
general toxicity of PTX [11]. NT4 derivatives are therefore very promising tumor-targeting agents 
that may enable high and broad cancer selectivity. 
Considering the potential of PTX as a chemotherapeutic drug, and the extremely promising 
results obtained by us with NT4-PTX, PTX has been the drug of choice for the construction of new 
drug-armed chemotherapeutics that deliver multiple units of cytotoxic drug to tumor tissue. NT4 
peptide was conjugated with one, two, and three units of paclitaxel and the cytotoxic effect was tested 
in vitro on the human colon adenocarcinoma cell line HT-29. The conjugation of more than one unit 
of paclitaxel with NT4 proved to have no additional impact on the overall cytotoxicity, indeed NT4-
mono PTX, NT4-bis PTX and NT4-tris PTX had the same cytotoxic effect in vitro.  
Release of PTX from the ester bond by hydrolysis is considered crucial for the efficacy of peptide-
bound drugs. In our previous study, the maleimido-propionic acid ester derivative NT4-PTX [11] 
achieved a higher EC50 than the three new NT4-PTX adducts reported above, which are hexanoic 
acid ester derivatives. We therefore infer that with these NT4-PTX adducts, increased loading of 
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active drug on the carrier was not accompanied by efficient ester hydrolysis, resulting in poor 
efficacy. The lack of correlation between the number of PTX units per NT4 molecule and efficacy may 
also be ascribed to decreased solubility of the adducts. Every PTX moiety that is added to NT4 makes 
the peptide more hydrophobic and probably decreases its availability in the cell medium. 
The second strategy we tested aimed at maximizing the drug delivery at the tumor site by 
developing NT4-based nanosystems, using NIR-emitting quantum dots. QD nanoparticles were 
linked to the tumor-targeted carrier, i.e., the NT4 peptide, and the cytotoxic moiety, PTX, to obtain a 
nanodevice NT4-QD-PTX designed to simultaneously detect and kill tumor cells. NT4-QDs, which 
we had already obtained and tested in previous in vitro and in vivo studies, were conjugated with 
PTX to obtain cancer-selective theranostics for in vivo diagnosis and therapy. Selective binding to 
HT-29 cells was confirmed by flow cytometry and confocal microscopy for NT4-QD-PTX with respect 
to unlabeled QD-PTX. NT4-QD-PTX cytotoxicity was tested in vitro on the HT-29 cell line and proved 
to be higher than that of QD-PTX.  
Since the advantages of tumor-selective uptake of NT4 peptides cannot be appreciated in 
experiments with a single cell population but are designed to be exploited in vivo, where increased 
local concentrations are evident and crucial, the results achieved so far with NT4-QD-PTX seem 
promising for further development as selective chemotherapeutics and specific in vivo tumor-cell 
tracers with diagnostic and therapeutic utility. 
4. Materials and Methods  
4.1. Mono, Bis, and Tris-PTX Maleimide Construction 
All the reactions were monitored by TLC on commercially available precoated silica gel 60 F 254 
plates) and the products were visualized with acidic vanillin solution. Silica gel 60, 230–400 mesh, 
was used for column chromatography. 1H and 13C-NMR spectra were recorded with a Varian Gemini 
200 or Varian Mercury Plus 400 using D-Chloroform (CDCl3) as solvent. The signal at 7.26 ppm of 
the residual CHCl3 in 1H-NMR spectra and at 77.0 ppm in the 13C-NMR spectra were used as 
reference. FT-IR spectra were recorded in CDCl3 solutions with a Perkin-Elmer 1600 FTIR 
Spectrometer (PerkinElmer, Waltham, MA, USA). ESI-MS spectra were measured either in positive 
and negative mode with a JEOL JMS700 MStation (JEOL Ltd. Akishima, Tokyo, Japan). Commercial 
reagents, catalysts, and ligands were used as obtained, unless otherwise stated, from freshly opened 
containers without further purification. Dry dichloromethane (DCM), diethyl ether (Et2O), 
tetrahydrofuran (THF), and dimethylformamide (DMF) were obtained from Pure Solv Micro devices 
(Sigma Aldrich, St. Louis, MO, USA Acetone was distilled over calcium chloride. 
Synthesis of PTX-N3 (Scheme 1 step a) 
 
DMAP (6 mg, 0.05 mmol) was added to a solution of Paclitaxel (PTX, 200 mg, 0.23 mmol) in dry 
DCM (8 mL) under N2. The colorless solution was cooled to 0 °C, then 6-azido-hexanoic acid (44 mg, 
0.28 mmol) was added, followed by DCC (58 mg, 0.28 mmol). The reaction mixture was stirred for 24 
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h, at reflux, under N2, then poured onto DCM (15 mL) and washed with a saturated solution of NH4Cl 
(3 × 40 mL) and a saturated solution of NaHCO3 (3 × 40 mL) followed by a saturated solution of NH4Cl 
(3 × 40 mL). The organic layer was dried over Na2SO4, filtered and evaporated. The crude product 
was purified by flash column chromatography using EP:AcOEt 1:1 as eluent to obtain PTX-N3 (195 
mg, 85% yield). Spectroscopic data was in line with the literature [22]. 1H-NMR (400 MHz, CDCl3) δ 
1.14 (s, 3H), 1.23 (s, 3H), 1.31–1.38 (m, 4H), 1.52–1.63 (m, 3H), 1.68 (s, 3H), 1.94 (s, 3H), 2.17 (s, 1H), 
2.23 (s, 3H), 2.33–2.42 (m, 2H), 2.46 (s, 3H), 2.48–2.60 (m, 2H), 3.21 (t, J = 6.8 Hz, 2H), 3.82 (d, J = 7.2 
Hz, 1H), 4.20 (d, J = 8.8 Hz, 1H), 4.31 (d, J = 8.8 Hz, 1H), 4.42–4.47 (m, 1H), 4.97 (d, J = 9.6 Hz, 1H), 5.51 
(d, J = 3.6 Hz, 1H), 5.68 (d, J = 7.2 Hz, 1H), 5.96 (dd, J = 12.0 Hz, J = 2.8 Hz, 1H), 6.25 (t, J = 10.0 Hz, 1H), 
6.29 (s, 1H), 6.88 (d, J = 9.2 Hz, 1H), 7.34–7.63 (m, 11H), 7.74 (d, J = 8.4 Hz, 2H), 8.13 (d, J = 8.4 Hz, 2H) 
ppm. FT-IR (CDCl3) N3 stretc. 2200 cm−1. 
Synthesis of mono-, bis- and tris-propargyl succinimide derivatives 2a–c (Scheme 1, steps b–d) 
b) Propargylation. General procedure: 18-crown-6 (0.01 mmol) and propargyl bromide (6.00 
mmol) were added in sequence under N2 to a solution of proper hydroxy-benzoic acid ethyl ester 
(1a–3a) in dry acetone and solid K2CO3 (6.00 mmol). The suspension was stirred at reflux for 24 h. 
Acetone was evaporated, water (30 mL) was added and the mixture was extracted with DCM (3 × 30 
mL). The organic phase was dried over Na2SO4, filtered and evaporated to obtain target compounds 
in nearly quantitative yield, used without further purification. 
4-prop-2-ynyloxy-benzoic acid ethyl ester (1a) 
 
Following the general procedure, 600 mg (>98% yield) of target compound as a brown oil was 
obtained from 4-hydroxy-benzoic acid ethyl ester (1a, 500 mg, 3.01 mmol). 1H-NMR (200 MHz, 
CDCl3) δ 1.38 (t, J = 7.6 Hz, 3H), 2.55 (t, J = 2.4Hz, 1H), 4.35 (q, J = 7.6 Hz, 2H), 4.75 (d, J = 2.4Hz, 2H), 
6.99 (m, 2H), 8.02 (m, 2H) ppm. FT-IR (CDCl3) 2258, 3308 cm−1. 
3,4-Bis-prop-2-ynyloxy-benzoic acid ethyl ester (1b) 
 
Following the general procedure, 297 mg (81% yield) of the target product was obtained from 
3,4-dihydroxy-benzoic acid ethyl ester (1b, 258 mg, 1.42 mmol). 1H-NMR (400 MHz, CDCl3) δ 1.37 (t, 
J = 7.2 Hz, 3H), 2.53 (t, J = 2.4 Hz, 2H), 4.35 (q, J = 7.2 Hz, 2H), 4.80 (d, J = 2.4 Hz, 2H), 4.81 (d, J = 2.4 
Hz, 2H), 7.06 (d, J = 9.2 Hz, 1H), 7.71-7.73 (m, 2H) ppm. 13C-NMR (100 MHz, CDCl3) δ 14.3, 56.6, 56.9, 
60.9, 76.2, 76.4, 77.7, 77.9, 113.1, 115.4, 124.0, 124.2, 146.8, 151.2, 166.0 ppm. FT-IR (CDCl3) 2260, 3307 
cm-1. ESI-MS: m/z = 208.08 [M + Na]+. 
3,4,5-tris-prop-2-ynyloxy-benzoic acid ethyl ester (1c) 
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Following the general procedure, 830 mg (>98% yield) of target compound was obtained from 
ethyl gallate (1c, 500 mg, 2.52 mmol) [23]. 1H-NMR (400 MHz, CD3OD) δ 1.38 (t, J = 7.2 Hz, 3H), 2.86 
(t, J = 2.4 Hz, 1H), 3.00 (t, J = 2.4 Hz, 2H), 4.36 (q, J = 7.2 Hz, 2H), 4.78 (d, J = 2.4 Hz, 2H), 4.83 (d, J = 2.4 
Hz, 4H), 7.47 (s, 2H) ppm. FT-IR (CDCl3) 2256, 3308 cm−1. 
c) Reduction. General procedure: A suspension with an excess of LiAlH4 (5.00 mmol) in dry THF 
was cooled to 0 °C and a 0.6 M solution of propynyloxy-benzoic esters in dry THF was added 
dropwise. The reaction mixtures were stirred overnight at r.t. under N2, then cooled to 0 °C and a 
saturated solution of NH4Cl was added. The mixtures were acidified to pH = 2 with HCl 10%, then 
extracted with DCM, dried over Na2SO4, filtered and evaporated to obtain the benzyl alcohols in 
nearly quantitative yields as pure compounds used without further purification. 
Synthesis of (4-(prop-2-yn-1-yloxy)phenyl)methanol 
 
Following the general procedure, the corresponding benzyl alcohol at 95% yield was obtained 
from 4-prop-2-ynyloxy-ethyl benzoate (369 mg, 1.81 mmol). 1H-NMR (200 MHz, CDCl3) δ 2.52 (t, J = 
2.4 Hz, 1H), 4.64 (s, 1H), 4.70 (d, J = 2.4 Hz, 2H), 6.95–7.02 (m, 2H), 7.30–7.35 (m, 2H) ppm. 
Synthesis of (3,4-bis(prop-2-yn-1-yloxy)phenyl)methanol 
 
Following the general procedure, the corresponding benzyl alcohol was obtained at 86% yield 
from 3,4-bis-prop-2-ynyloxy-benzoic acid ethyl ester (140 mg, 0.54 mmol) [24]. 
Synthesis of (3,4,5-tris-prop-2-ynyloxy-phenyl)-methanol  
 
Following the general procedure, the corresponding benzyl alcohol was obtained at 95% yield 
from 3,4,5-tris-prop-2-ynyloxy-benzoic acid ethyl ester (1.40 g, 4.48 mmol) [22]. 
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d) Mitsunobu reaction. General procedure: DIAD (1.1 mmol) was added dropwise to a solution 
of PPh3 (1.1 mmol) in dry THF (6 mL) cooled to 0 °C. After 5 minutes a solution of benzyl alcohol 
derivative (1.0 mmol) in dry THF (18 mL) was added, followed by maleimide (1.0 mmol) in dry THF 
(6 mL). The reaction was microwave heated as reported below. Then THF was evaporated and the 
crude products purified by flash column chromatography. 
Synthesis of 1-(4-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione (2a) 
 
Following the general procedure, after microwave irradiation at 100 °C for 1 h and 120 °C for 45 
min, 4-prop-2-ynyloxy-phenyl)-methanol (153 mg, 0.94 mmol) was used to obtain a crude product 
which was purified by flash column chromatography using DCM as eluent to obtain 2a (43 mg, 21% 
yield) as a colorless solid (m.p. 109–110 °C). 1H-NMR (400 MHz, CDCl3) δ 2.50 (t, J = 2.0 Hz, 1H), 4.61 
(s, 2H), 4.66 (d, J = 2.0 Hz, 2H), 6.69 (s, 2H), 6.91 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H) ppm. 13C-
NMR (100 MHz, CDCl3) δ 40.7, 55.7, 75.6, 78.4, 114.9, 129.3, 129.8, 134.1, 157.1, 170.4 ppm. FT-IR 
(CDCl3) 1711, 1732, 2258, 3308 cm−1. 
Synthesis of 1-(3,4-bis-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione (2b) 
 
Following the general procedure, after microwave irradiation at 120 °C for 80 min., 3,5-bis-prop-
2-ynyloxy-phenyl)-methanol (70 mg, 0.32 mmol) was used to obtain a crude product that was 
purified by flash column chromatography using DCM:Et2O 10:1 as eluent to obtain 2b (28 mg, 33% 
yield) as a colorless solid (m.p. 127–129 °C). 1H-NMR (400 MHz, CDCl3) δ 2.49 (t, J = 2.4 Hz, 1H), 2.51 
(t, J = 2.4 Hz, 1H), 4.61 (s, 2H), 4.72 (d, J = 2.4 Hz, 2H), 4.73 (d, J = 2.4 Hz, 2H), 6.69 (s, 2H), 6.96–6.97 
(m ,2H), 7.06 (d, J = 1.2 Hz, 1H) ppm. 13C-NMR (100 MHz, CDCl3) δ 41.0, 56.8, 56.9, 75.9, 76.0, 78.2, 
78.4, 114.7, 115.3, 122.2, 130.1, 134.2, 147.1, 147.4, 170.3 ppm. FT-IR (CDCl3) 1711, 1732, 3307 cm−1. ESI-
MS: m/z = 318.17 [M + Na]+. 
Synthesis of 1-(3,4,5-tris-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione (2c) 
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Following the general procedure, after microwave irradiation at 80 °C for 30 min and 100 °C for 
1 h, 3,4,5-tris-prop-2-ynyloxy-phenyl)methanol (100 mg, 0.37 mmol) was used to obtain a crude 
product which was purified by flash column chromatography using DCM:Et2O 30:1 as eluent to 
obtain 2c (27 mg, 22% yield) as a colorless solid (m.p. 120–122 °C). 1H-NMR (400 MHz, CDCl3) δ 2.45 
(t, J = 2.4 Hz, 1H), 2.51 (t, J = 2.4 Hz, 2H), 4.60 (s, 2H), 4.68 (d, J = 2.4 Hz, 2H), 4.73 (d, J = 2.4 Hz, 4H), 
6.72 (s, 2H), 6.75 (s, 2H) ppm. 13C-NMR (100 MHz, CDCl3) δ 41.4, 57.0, 60.3, 75.2, 76.0, 78.2, 79.1, 108.8, 
132.3, 134.2, 136.7, 151.5, 170.2 ppm. FT-IR (CDCl3) 1711, 3308 cm−1. ESI-MS: m/z = 372.17 [M + Na]+. 
General Procedure for the Huisgen click reaction (Scheme 1, step e) 
e) General procedure: CuSO4 (0.006 mmol) and sodium ascorbate (0.01 mmol) were added in 
sequence to a solution of maleimide-propynyloxy derivatives 2a–c (0.04 mmol, in DMF 1mL). After 
5 min, PTX-N3 (0.05 mmol in 1 mL DMF:H2O 3:1) was added and the mixture stirred at r.t. for 24–48 
h. H2O (10 mL) was then added to the mixture and extracted with DCM (4 × 10 mL). The organic 
phases were washed with H2O until the complete removal of DMF, dried over Na2SO4, filtered and 
evaporated to dryness. The crude product was purified by flash column chromatography. 
Synthesis of mono-PTX-maleimide adduct (3a)  
 
Following the general procedure from 1-(4-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione 2a (10 mg, 
0.04 mmol) and PTX-N3 (49 mg, 0.05 mmol). The solution was stirred at r.t. for 24 h, and the crude 
product purified by flash column chromatography using AcOEt:EP 5:1 as eluent to obtain derivative 
3a (21 mg, 42% yield) as a white solid. 1H-NMR (400 MHz, CDCl3) δ 1.13 (s, 3H), 1.23 (s, 3H), 1.25–
1.31 (m, 3H), 1.57–1.64 (m, 2H), 1.68 (s, 3H), 1.82–1.89 (m, 3H), 1.93 (s, 3H), 2.08–2.14 (m, 1H), 2.22 (s, 
3H), 2.29–2.41 (m, 3H), 2.44 (s, 3H), 2.51–2.59 (m, 2H), 3.80 (d, J = 6.8 Hz, 1H), 4.18–4.32 (m, 4H), 4.41–
4.47 (m, 1H), 4.60 (s, 2H), 4.96 (d, J = 8.8 Hz, 1H), 5.16 (s, 2H), 5.49 (d, J = 4.0 Hz, 1H), 5.68 (d, J = 7.2 
Hz, 1H), 5.96 (dd, J = 9.6 Hz, J = 4.0 Hz, 1H), 6.22 (t, J = 8.0 Hz, 1H), 6.29 (s, 1H), 6.67 (s, 2H), 6.90 (d, J 
= 8.8 Hz, 2H), 7.07 (d, J = 9.2 Hz, 1H), 7.28–7.63 (m, 12H), 7.72 (d, J = 7.2 Hz, 2H), 8.13 (d, J = 7.2 Hz, 
2H) ppm. 13C-NMR (100 MHz, CDCl3) δ 9.5, 14.7, 20.8, 22.1, 22.6, 23.8, 25.5, 26.7, 29.6, 33.3, 35.50, 35.52, 
40.7, 43.1, 45.5, 49.8, 52.8, 58.4, 62.0, 71.7, 72.0, 74.0, 75.0, 75.5, 76.4, 79.0, 81.0, 84.4, 114.8, 122.5, 126.5, 
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127.0, 128.4, 128.6, 129.04, 129.08, 129.1, 129.8, 130.1, 131.9, 132.7, 133.64, 133.67, 134.1, 136.8, 142.6, 
144.1, 157.7, 166.9, 167.1, 168.1, 169.8, 170.4, 171.1, 172.2, 203.7 ppm. ESI-MS: m/z = 1256.42 [M + Na]+ 
(supplementary Figure S1). 
Synthesis of bis-PTX-maleimide adduct (3b) 
 
Following the general procedure from 1-(3,4-bis-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione 2b 
(15 mg, 0.05 mmol) and PTX-N3 (49 mg, 0.05 mmol). The solution was stirred at r.t. for 24 h, and the 
crude product purified by flash column chromatography using AcOEt:EP 5:1 as eluent to obtain 
derivative 3b (27 mg, 23% yield) as a pale brown solid. 1H-NMR (400 MHz, CDCl3) δ 1.12–1.25 (m, 
18H), 1.56–1.75 (m, 10H), 1.75–1.92 (m, 16H), 2.04–2.10 (m, 4H), 2.20 (s, 6H), 2.26–2.37 (m, 6H), 2.43 (s, 
6H), 2.49–2.62 (m, 4H), 3.79 (d, J = 7.2 Hz, 2H), 4.18 (d, J = 7.6 Hz, 2H), 4.29 (d, J = 8.4 Hz, 2H), 4.41–
4.46 (m, 2H), 4.55 (s, 2H), 4.95 (d, J = 9.6 Hz, 2H), 5.17 (s, 1H), 5.19 (s, 1H), 5.50 (d, J = 4.0 Hz, 2H), 5.66 
(d, J = 6.8 Hz, 2H), 5.94 (dd, J = 4.0 Hz, J = 9.2 Hz, 2H), 6.20 (t, J = 8.0 Hz, 2H), 6.29 (s, 2H), 6.66 (s, 2H), 
6.93–6.95 (m, 1H), 7.15–7.18 (m, 2H), 7.29–7.63 (m, 24H), 7.71 (d, J = 7.6 Hz, 4H), 8.12 (d, J = 7.2 Hz, 
4H) ppm. 13C-NMR (100 MHz, CDCl3) δ 9.6, 14.8, 20.8, 22.1, 22.7, 23.8, 25.5, 26.8, 29.6, 33.3, 35.4, 35.6, 
43.1, 45.6, 49.8, 53.0, 58.4, 71.7, 72.0, 74.1, 75.0, 75.6, 79.1, 81.0, 84.4, 126.7, 127.1, 128.5, 128.6, 128.7, 
129.0, 129.2, 130.2, 131.9, 132.8, 133.6, 133.7, 134.2, 137.0, 142.7, 167.0, 167.1, 168.2, 169.8, 170.4, 171.1, 
172.3, 203.7 ppm. FT-IR (CDCl3) 1713, 2248, 2258, 2944, 3447, 3524, 3567 cm-1. ESI-MS: m/z = 2303.88 
[M + Na]+ (supplementary Figure S2). 
Synthesis of tris-PTX-maleimide adduct (3c) 
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Following the general procedure from 1-(3,4,5-tris-prop-2-ynyloxy-benzyl)-pyrrole-2,5-dione 2c 
(8 mg, 0.02 mmol) and PTX-N3 (49 mg, 0.05 mmol). The solution was stirred at r.t. for 48 h, and the 
crude product was purified by flash column chromatography using DCM:MeOH 10:1 as the eluent 
to obtain derivative 3c (12 mg, 16% yield) as a white solid. 1H-NMR (400 MHz, CDCl3) δ 1.12 (s, 9H), 
1.25 (s, 9H), 1.25–1.40 (m, 6H), 1.54–1.62 (m, 6H), 1.66–1.96 (m, 12H), 1.79–1.87 (m, 4H), 1.91 (s, 9H), 
2.05–2.11 (m, 3H), 2.20 (s, 9H), 2.25–2.36 (m, 9H), 2.42 (s, 9H), 2.49–2.66 (m, 6H), 3.42–3.50 (m, 3H), 
3.78 (d, J = 7.2 Hz, 3H), 4.09–4.31 (m, 15H), 4.40–4.53 (m, 3H), 4.95 (d, J = 9.6 Hz, 3H), 5.07–5.15 (m, 
4H), 5.48 (d, J = 4.0 Hz, 3H), 5.66 (d, J = 6.8 Hz, 3H), 5.93 (dd, J = 6.8 Hz, J = 4.4 Hz, 3H), 6.17–6.23 (m, 
3H), 6.29 (s, 3H), 6.66 (s, 2H), 6.69 (s, 2H), 7.31–7.53 (m, 27H), 7.59–7.73 (m, 12H), 8.12 (d, J = 8.4 Hz, 
6H) ppm. 13C (100 MHz, CDCl3) δ 9.6, 14.8, 20.8, 22.05, 22.08, 22.7, 23.8, 24.9, 25.5, 26.7, 29.60, 29.64, 
29.68, 33.2, 33.9, 43.1, 49.1, 49.8, 58.4, 75.5, 79.0, 80.9, 84.3, 84.4, 126.7, 127.1, 128.64, 128.69, 129.0, 129.1, 
130.1, 133.6, 136.9, 166.9, 167.1, 168.2, 169.8, 170.3, 171.1, 172.3, 203.7. FT-IR (CDCl3) 1713, 2801, 2860, 
3308, 3435 cm−1. ESI-MS: m/z = 1665.17 [(M + 2H)/2]+ (supplementary Figure S3). 
4.2. Peptide Synthesis  
Solid-phase synthesis was carried out on a MultiSynTech Syro automated multiple peptide 
synthesizer (Witten, Germany), employing Fmoc chemistry with 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate/N,N-diisopropylethylamine (HBTU/DIPEA) activation. 
NT4-Cys was synthesized on TG S RAM resin using Fmoc-Cys(Trt)-OH as first, and Fmoc-PEG12-
OH (Iris Biotech, Germany) as the second coupling step. Then two coupling steps with Fmoc-
Lys(Fmoc)-OH were used to build the core. Pyro-glu-O-pentachlorophenylester was used for the N-
terminal acid of the neurotensin sequence. Peptides were cleaved from the resins and deprotected by 
treatment with trifluoroacetic acid containing water and triisopropylsilane (95:2.5:2.5) for 1.5 hours 
at room temperature. After precipitation with diethyl ether, branched peptides were purified by RP-
HPLC. Final peptide purity was confirmed to exceed by 99% C18 Jupiter column HPLC 
(Phenomenex, 300 Å, 5 µm, 250 × 4.6 mm) using 0.1% TFA/water as eluent A and acetonitrile as eluent 
B with a linear gradient from 75% A to 65% A in 40 min. All peptides were characterized by 
UltraflexIII MALDI TOF/TOF mass spectrometry (Bruker Daltonics, Bremen, Germany). Commercial 
reagents, catalysts, and ligands were used without further purification from freshly opened 
containers, unless otherwise stated.  
4.3. NT4-mono PTX, NT4-bis PTX, and NT4-tris PTX construction 
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Mono, bis or tris PTX maleimide derivatives reacted with NT4-Cys, in DMF, at 
maleimide:peptide:DIPEA molar ratio 5:1:1. The reaction mixture was left under stirring for 20 hours 
or 48 hours (for NT4-tris PTX). Then each conjugate was purified by RP-HPLC on a semi-preparative 
C18 Jupiter column (Phenomenex, 300 Å, 10 µm, 250 × 10 mm) using 0.1% TFA/water as eluent A and 
acetonitrile as eluent B with a two-step linear gradient from 80% A to 20% A in 30 min and from 20% 
A to 5% A in 5 min. All conjugates were characterized by UltraflexIII MALDI TOF/TOF mass 
spectrometry (Bruker Daltonics, Bremen, Germany). The final products were more than 90% pure, 
calculated on HPLC spectra. MS spectra showed the main peaks at the expected molecular masses: 
8958 [NT4-mono PTX + H]+, 10005 [NT4-bis PTX + H]+ and 11052 [NT4-tris PTX + H]+. 


















Succinic anhydride (0.014 g, 0.14 mmol) and DMAP (0.003 g, 0.02 mmol) were added in sequence 
to a solution of paclitaxel (PTX, 0.1 g, 0.12 mmol) in 4 mL dry pyridine. The solution was stirred for 
3 h at r.t under N2. The solvent was vacuum-evaporated to obtain a colorless oil. The crude product 
was dissolved in 20 mL DCM and washed with a saturated solution of NH4Cl (3 × 40 mL), followed 
by water (3 x 40 mL), to remove residual pyridine. The organic layer was dried over Na2SO4, filtered 
and evaporated to obtain PTX-COOH as a white solid (43 mg, 38% yield). Spectroscopic data was in 
line with the literature [25]. ESI-MS spectra were measured either in the negative or positive mode: 
m/z = 852.17 [M − succ]−, 952.17 [M − H]−, 1906.00 [2M − H]−; 976.17 [M + Na]+. 
Synthesis of PTX-NSuc (step b of Scheme 3) 
 
Diphenyl chlorophosphate (268.6 mg, 1.0 mmol) and triethylamine (101.19 mg, 1.0 mmol) were 
added in sequence to a solution of N-hydroxysuccinimide (115 mg, 1.0 mmol) in dry DCM (4 mL) 
and the mixture stirred at r.t. for 2 hours [26]. The solvent was evaporated and the crude product was 
dissolved in ethyl acetate (10 mL) and washed with a saturated aqueous solution of NaCl (3 × 10 mL). 
The organic layer was dried over Na2SO4, filtered and evaporated to obtain N-succinimidyl 
diphenylphosphate (SDDP) in nearly quantitative yield, which was used without purification in the 
next step. Freshly prepared succinimidyl diphenylphosphate (18 mg, 0.053 mmol) and triethylamine 
(14 mg, 0.14 mmol) were added in sequence to a solution of PTX-COOH (40 mg, 0.035 mmol) in dry 
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acetonitrile (1.2 mL). The mixture was stirred under nitrogen for 6 hours, and the solvent vacuum-
evaporated. The crude product was purified by flash column chromatography to obtain PTX-Nsuc 
(18 mg, 51% yield) as a white solid. Spectroscopic data was in line with previous reports [23]. 1H-
NMR (300 MHz, CDCl3) δ 8.14 (d, J = 6.9, 2H), 7.71 (d, J = 6.9, 2H), 7.61 (t, J = 7.5 Hz,1H), 7.54–7.33 (m, 
10H), 6.30 (s, 1H), 6.28 (t, J = 8.4, 1H), 5.98 (dd, J = 9.3, 3.0, 1H), 5.69 (d, J = 7.5, 1H), 5.48 (d, J = 3.0, 1H), 
4.99 (d, J = 8.4, 1H), 4.45 (dd, J = 10.7, 6.2 1H), 4.32 (d, J = 7.8, 1H), 4.21 (d, J = 8.7, 1H), 3.82 (d, J = 7.2, 
1H), 2.91–2.51 (m, 8H), 2.49 (s, 3H), 2.38 (t, J = 7.5 Hz, 2H), 2.23 (s, 3H), 2.21–2.02 (m, 3H), 1.95 (s, 3H), 
1.86 (m, 1H), 1.68(s, 3H), 1.24 (s, 3H), 1.14 (s, 3H) ppm. ESI-MS: m/z = 1073.25 [M + Na]+ 
(supplementary Figure S4). 
4.4. NT4-QD-PTX Construction 
Qdot 705 ITK amino PEG (Qdot 705 ITK™ Amino (PEG) Quantum Dots, Molecular Probes) were 
transferred to phosphate buffered saline (PBS, pH 7.4) using a PES 100K MWCO protein concentrator 
(Thermo Fisher Scientific, Waltham, MA, USA) spun at 3800× g at 4 °C. Quantum dots were then 
conjugated with sulfo-SMCC (sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate; 
Thermo Fisher Scientific) for 1 hour at room temperature on a rotator ALC 120R (Thermo Fisher 
Scientific) to generate a maleimide-activated surface on the QDs, using a QDs:sulfo-SMCC 1:20 molar 
ratio, which corresponds to a ratio of NH2:sulfo-SMCC 5:1. Then PTX-Nsuc (50 equivalents with 
respect to QDs) was added to the mixture and left to react for 1 hour. Free sulfo-SMCC and free PTX-
Nsuc were removed using a NAP-5 column (GE Healthcare, Chicago, IL, USA). The isolated 
maleimide-QD-PTX was incubated with NT4-Cys for 1 hour at room temperature on the rotator, 
using a QDs:NT4-Cys 1:50 molar ratio. Total of 10 mM 2-mercaptoethanol was added to the reaction 
and left for an additional 30 minutes to cap unreacted maleimides. NT4-conjugated QD-PTX was 
further purified on a Superdex 200 column, eluting with 20 mM phosphate buffer (pH 7.4). The 
concentration of quantum dots was examined using a spectrophotometer at 532 nm and an extinction 
coefficient of 2.1 × 106 (mol/L)−1 cm−1. The 1H-NMR spectrum showed the signals of PTX and NT4. 
4.5. NMR Measurements 
Solution NMR spectra were recorded at 298 K on Bruker AVANCEIII-HD (Bruker, Billerica, MA, 
USA) and AVANCE NEO NMR spectrometers operating at 950 MHz and 900 MHz (1H Larmor 
frequency), respectively. Both instruments were equipped with triple resonance cryo-probes for high 
sensitivity. The samples were prepared by dissolving QDs in PBS with 10% D2O. The spectra for NT4-
QD-PTX, QD-PTX, and undecorated QDs were acquired with 8192, 16384, and 1024 scans, 
respectively. All the spectra were recorded with a relaxation delay of 3 s. 
4.6. Cell Cultures 
Human colon adenocarcinoma HT-29 cells were grown in McCoy’s 5a Medium supplemented 
with 10% fetal bovine serum, 200 µg/mL glutamine, 100 µg/mL streptomycin, and 60 µg/mL 
penicillin. They were maintained under 5% CO2. The cell line was purchased from ATCC (The Global 
Bioresource Center, Manassas, VA, USA). 
4.7. In Vitro Cytotoxicity Assay 
HT-29 cells were plated at a density of 5 × 103 per well in 96-well microplates. Different peptide 
concentrations (NT4-mono PTX, NT4-bis PTX, NT4-tris PTX, NT4-QD-PTX and undecorated QD-
PTX) were added 24 h after plating. Cells were washed after 1 h incubation and then left for 6 days 
at 37 °C in the same medium. Growth inhibition was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). The experiment was performed twice in triplicate. EC50 values 
were calculated by non-linear regression analysis using GraphPad Prism 5.03 software (San Diego, 
CA, USA). 
4.8. NT4-QD-PTX Binding by Flow Cytometry 
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100,000 cells/experiment were incubated in 96-well U-bottom plates for 30 minutes at room 
temperature with different concentrations of NT4-QDs (5 nM, 10 nM, and 20 nM) in PBS-EDTA 5 
mM-BSA 0.5%. Flow cytometric analysis was performed with 10,000 events using a BD FACS Canto 
II instrument (BD, NJ. USA). Assays were performed in triplicate and the flow cytometry results were 
analyzed by nonlinear regression analysis using GraphPad Prism 5.03 software.  
4.9. NT4-QD-PTX Binding by Immunofluorescence 
The binding of NT4-QD-PTX and unlabeled QD-PTX was tested in HT-29 cells. Total of 3 × 104 
cells/well were seeded on 24-well plates, grown for 24 hours and then incubated with 20 nM NT4-
QDs or with unlabeled QDs for 30 min at 37 °C in PBS-1% BSA. After 30 minutes of incubation, the 
cells were fixed with PBS 4% formalin. Each step was followed by three washes in PBS. Samples were 
mounted using Prolong Gold antifade with DAPI (Molecular Probes, Eugene, OR, USA) and 
analyzed by confocal laser microscope (Leica TCS SP5) with 380 nm 𝜆ex and 680–750 nm 𝜆em and 
380 nm 𝜆ex and 450–470 nm 𝜆em for NIR-QDs and DAPI, respectively. All images were processed 
using ImageJ software (NIH, Rockville, MD, USA). 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1. Figure S1: Structure, 
1H-NMR and 13C-NMR of mono-PTX-maleimide. Figure S2: Structure, 1H-NMR and 13C-NMR of bis-PTX-
maleimide. Figure S3: Structure, 1H-NMR and 13C NMR of tris-PTX-maleimide. Figure S4: Structure, 1H-NMR 
and 13C NMR of PTX-NSuc. 
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